SecBot SecBot

SNGX drug pipeline

SOLIGENIX, INC. · 3 rated drugs
$0.2900
−9.4% 1-day · Nov 16
Next catalyst
None dated
No dated FDA catalyst on file
Typical move on FDA news
No history
No past FDA events with prices
IV rank
No data
No current options data
Rated drugs
3
1 bearish · 2 neutral
Phase 3 trials
1
0 with results posted

Drugs

soonest catalyst first
● neutral
Impact
PhasePhase 2
Time to marketAt least 3-5 years away, assuming a successful Phase 2b/3 program is initiated and completed. The company has not announced a registrational trial start date and may need a partner to fund it.

SGX945 dusquetide Updated Nov 9

What to watch

Watch for any announcement from Soligenix regarding the next development steps for SGX945, including potential Phase 3 trial plans or a partnership/licensing deal. The company is actively evaluating strategic alternatives, so any M&A or partnership news could be a major catalyst. Also monitor for any new clinical trial initiations or regulatory milestone updates.

Bull case
  • SGX945 (dusquetide) achieved 7 of 8 patients with complete response of oral ulcers in a Phase 2a proof-of-concept study, with no treatment-related adverse events, comparing favorably to Otezla's side effect profile (diarrhea 41%, nausea 19%, headache 14%).
  • The drug has received multiple regulatory designations: FDA Fast Track (Jan 2024), FDA Orphan Drug (Aug 2025), EMA positive opinion and EU Orphan Drug (Feb-Mar 2026), and UK MHRA Promising Innovative Medicine designation (Mar 2026), indicating regulatory support.
  • SGX945 uses a novel innate defense regulator (IDR) mechanism that modulates the immune system rather than suppressing it, potentially offering a differentiated safety profile versus existing treatments.
Bear case
  • Soligenix has a market cap of roughly $7.6M and only $9.0M in cash (as of September 30, 2026), limiting its ability to fund a large Phase 3 trial without significant dilution or a partnership.
  • The Phase 3 FLASH2 trial for HyBryte (the company's other lead asset) was terminated in 2026 after disappointing interim results, raising questions about Soligenix's clinical development capabilities.
  • The company has conducted multiple ATM equity offerings in 2026, causing substantial shareholder dilution. The stock trades around $0.335, near its 52-week low of $0.28.
● neutral
Impact
PhasePhase 1c (initiated 2019, no reported results)
Time to marketUncertain; the program is in early-stage development under the FDA Animal Rule pathway. No pivotal or registrational trials have been announced.

RiVax ricin toxin A-chain subunit vaccine Updated Nov 9

What to watch

RiVax is a biodefense vaccine with no near-term binary catalyst. The program has orphan drug designation and has shown positive preclinical correlates of protection in non-human primate ricin challenge studies, but no active clinical trial results have been reported since the Phase 1c was initiated in late 2019. Soligenix's cash position of roughly $9.0M as of September 30, 2026, is limited, and the company's primary focus appears to be its HyBryte CTCL program and SGX945 for Behcet's disease. Watch for any new NIAID/BARDA contract awards or Animal Rule meeting outcomes that could re-energize the program.

Bull case
  • RiVax is one of the most advanced ricin toxin vaccine candidates globally, with demonstrated up to 100% protection in non-human primate lethal ricin challenge studies.
  • The program has FDA Orphan Drug Designation and is being developed under the Animal Rule, which could enable a more efficient approval pathway using animal efficacy data.
  • NIAID has awarded up to $24.7M in contract funding for RiVax development, signaling government interest in biodefense stockpiling.
Bear case
  • No clinical trial results have been reported since the Phase 1c was initiated in December 2019, suggesting the program may be stalled or deprioritized.
  • Soligenix had only roughly $9.0M in cash as of September 30, 2026, with no revenue, and the company's recent Q3 2026 update did not mention RiVax progress.
  • The company's primary focus appears to be its HyBryte CTCL program (which had disappointing Phase 3 interim results in April 2026) and SGX945 for Behcet's disease, not RiVax.
▼ bearish
Impact
PhasePhase 2a (completed)
Time to marketAt least 3-5 years if development resumes; SGX302 has only completed a small Phase 2a trial (15 patients) and would need Phase 2b and Phase 3 trials before any regulatory submission. The company's strategic review and limited cash make the timeline highly uncertain.

SGX302 hypericin sodium Updated Nov 9

What to watch

SGX302 has no upcoming binary catalyst; the Phase 2a is complete and the company is exploring strategic alternatives after its lead CTCL program failed. Watch for a partnership or licensing deal for SGX302, or a broader M&A outcome for Soligenix itself. The Q3 2026 earnings press release (Nov 6) is the most recent update and noted the company is evaluating strategic alternatives.

Bull case
  • SGX302 (synthetic hypericin) showed positive Phase 2a signals: in Cohort 3 (Dec 2025), 3 of 4 patients achieved PASI 75 (75% improvement) with an optimized gel formulation, and the drug was well tolerated with no drug-related adverse events.
  • The active ingredient (hypericin sodium) has orphan drug designations and a known safety profile from the CTCL program; the FDA has already cleared the IND for SGX302.
  • Soligenix narrowed its Q3 2026 net loss to $1.12M (from $2.53M a year ago) and has cash runway into Q2 2028, giving it time to find a partner or strategic exit.
Bear case
  • Soligenix's lead asset HyBryte (SGX301, same active ingredient) failed its Phase 3 FLASH2 trial in April 2026, with the Data Monitoring Committee recommending the study be halted for futility, casting a shadow over the entire hypericin platform.
  • SGX302 is only in Phase 2a (12-15 patients total across cohorts), far from registration; a pivotal Phase 2b/3 program would require substantial capital that Soligenix, with only ~$9M cash and no revenue, likely cannot fund alone.
  • The company is exploring strategic alternatives (partnerships, M&A, licensing) after the FLASH2 failure, creating uncertainty about whether SGX302 will be developed further by Soligenix at all.

Other drugs in filings and trials

no drug report yet

Clinical trials

3 Phase 2/3
DrugTrialPhaseStatusEnrolledPrimary completion
HypericinConfirmatory Study of Topical HyBryte™ vs. Placebo for the Treatment of CTCLPhase 3Terminated70May 22, 2026
HypericinTopical SGX302 for Mild-to-Moderate PsoriasisPhase 2Completed15Oct 22, 2025
SGX945Dusquetide for the Treatment of Behcet's DiseasePhase 2Completed · results8May 23, 2025